| 1GSN Stock | | | EUR 147.00 0.00 0.00% |
Director
Mr. Brian D. King is Independent Director of the company. Mr. King serves as the president and chief executive officer, and a director, of MedPlast, Inc., a private global services provider to the medical device industry. From June 2014 to June 2015, Mr. King served as Chief Transformation Officer and Chief Operating Officer at DePuy Synthes, a Johnson Johnson company, which designs and manufactures orthopedic and neurological devices and supplies. From 2004 to 2014, Mr. King served in various executive positions at Covidien, formerly Tyco Healthcare, a global healthcare products company and manufacturer of medical devices and supplies, which was later acquired by Medtronic. At Covidien, Mr. King served as Group President, Emerging Markets, President, Covidien Asia, Senior Vice President, Global Operations and Quality, and Vice President, Operational Excellence . Mr. King has served as Operating Advisor at Thomas H. Lee Partners, a private equity firm, since June 2015. Mr. King currently serves on the board of directors of PCI Pharma Services, a privately held entity, and previously served on the board of directors of Houston Street Exchange, Inc. and BC Research Corporationrationration, both privately held entities. Mr. King holds an MBA from Harvard Business School, MS from the Pennsylvania State University, and BS from the United States Naval Academy since 2017.
| Age | 52 |
| Tenure | 7 years |
| Phone | 781 266 5700 |
| Web | https://www.novanta.com |
King’s 25 years of executive operating experience, the majority of which was spent in the healthcare industry, as well as his broad business background in global manufacturing, engineering, supply chain, quality assurance, and regulatory affairs, provides the Board with greater insight into the healthcare industry and makes him wellqualified to serve on the Board.
Novanta Management Efficiency
The company has return on total asset
(ROA) of
0.0534 % which means that it generated a profit of $0.0534 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.1392 %, meaning that it generated $0.1392 on every $100 dollars invested by stockholders. Novanta's management efficiency ratios could be used to measure how well Novanta manages its routine affairs as well as how well it operates its assets and liabilities.
Novanta has accumulated 429.36
M in total debt with debt to equity ratio
(D/E) of 0.53, which is about average as compared to similar companies. Novanta has a current ratio of 2.61, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Novanta until it has trouble settling it off, either with new capital or with free cash flow. So, Novanta's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novanta sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novanta to invest in growth at high rates of return. When we think about Novanta's use of debt, we should always consider it together with cash and equity.
Novanta Inc., together with its subsidiaries, designs, manufactures, markets, and sells photonics, vision, and precision motion components and sub-systems to original equipment manufacturers in the medical and industrial markets worldwide. Novanta Inc. was founded in 1968 and is headquartered in Bedford, Massachusetts. NOVANTA INC operates under Scientific Technical Instruments classification in Germany and is traded on Frankfurt Stock Exchange. It employs 2200 people. Novanta (1GSN) is traded on Frankfurt Exchange in Germany and employs 2,700 people.
Management Performance
Novanta Leadership Team
Elected by the shareholders, the Novanta's board of directors comprises two types of representatives: Novanta inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novanta. The board's role is to monitor Novanta's management team and ensure that shareholders' interests are well served. Novanta's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novanta's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephen Bershad, Independent Chairman of the Board | |
| Ray Nash, Corp Leader | |
| Michele Welsh, Gen Sec | |
| Sarah Betadam, Chief Officer | |
| Deborah Eldracher, Independent Director | |
| Heinrich Dreyer, Group Vision | |
| Ira Lamel, Independent Director | |
| Lonny Carpenter, Independent Director | |
| Brian King, Independent Director | |
| Peter Chang, Co Officer | |
| Brian Young, Chief Human Resource Officer | |
| Charlie Webster, Ex Chain | |
| Thomas Secor, Independent Director | |
| Deborah DiSanzo, Independent Director | |
| Matthijs Glastra, Chief Executive Officer, Director | |
| Chuck Ravetto, Group Group | |
| Robert Buckley, Chief Financial Officer | |
Novanta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novanta a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Novanta Stock
When determining whether Novanta is a good investment, qualitative aspects like company
management, corporate governance, and ethical practices play a significant role. A
comparison with peer companies also provides context and helps to understand if Novanta Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Novanta Stock.
Highlighted below are key reports to facilitate an investment decision about Novanta Stock: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in Novanta. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
For more detail on how to invest in Novanta Stock please use our
How to Invest in Novanta guide.
You can also try the
ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Please note, there is a significant difference between Novanta's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novanta is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novanta's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.